The Uromigos

AZGUONC-PRODUCTIONwarmup

<section data-encore-id="navBar">
<div class="NavBar__NavBarPage-sc-1guraqe-0 ejVULV">
<div class="qEoBuparvnBwiHsPzwEj">
<div class="TQXhY8PT8v1vogxO85c_">
<div class="e-9541-text encore-text-body-medium RKzJftL6TOVUXkXOPykT" data-encore-id="text">
<div class="xgmjVLxjqfcXK5BV_XyN">Romain Banchereau, PhD, joins the show to discuss and debate this <em>Cancer Cell</em> paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.</div>
</div>
</div>
</div>
</div>
</section>


Episode 381: Molecular Heterogeneity in Urothelial Carcinoma and Determinants of Clinical Benefit to PD-L1 Blockade

Romain Banchereau, PhD, joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoint blockade.

The Uromigos Episode 381: Molecular Heterogeneity in Urothelial Carcinoma

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe

Episode 381: Molecular Heterogeneity in Urothelial Carcinoma and Determinants of Clinical Benefit to PD-L1 Blockade

Related Podcasts